Ardent Health (NYSE:ARDT – Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.06), FiscalAI reports. Ardent Health had a net margin of 2.09% and a return on equity of 13.85%. The firm had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.59 billion. Ardent Health updated its FY 2026 guidance to 0.780-1.150 EPS.
Ardent Health Stock Down 0.1%
Shares of NYSE ARDT traded down $0.01 during trading hours on Tuesday, hitting $10.74. 413,105 shares of the stock were exchanged, compared to its average volume of 461,909. The company has a quick ratio of 2.00, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. The company has a market cap of $1.54 billion, a PE ratio of 11.30, a PEG ratio of 2.51 and a beta of 0.70. The firm has a fifty day moving average price of $9.83 and a 200-day moving average price of $9.43. Ardent Health has a 12 month low of $7.71 and a 12 month high of $15.48.
Insider Buying and Selling
In other news, CFO Alfred Lumsdaine bought 10,000 shares of the stock in a transaction on Friday, June 5th. The stock was bought at an average cost of $8.81 per share, for a total transaction of $88,100.00. Following the completion of the purchase, the chief financial officer directly owned 329,183 shares in the company, valued at approximately $2,900,102.23. The trade was a 3.13% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.90% of the stock is owned by insiders.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on ARDT shares. UBS Group increased their price objective on shares of Ardent Health from $13.00 to $13.50 and gave the company a “buy” rating in a research note on Thursday, May 7th. Royal Bank Of Canada lowered their target price on Ardent Health from $13.00 to $12.00 and set an “outperform” rating for the company in a report on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ardent Health in a research report on Friday, June 12th. Wall Street Zen downgraded Ardent Health from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Truist Financial reduced their price target on Ardent Health from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $14.04.
Ardent Health Company Profile
Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.
Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.
Further Reading
- Five stocks we like better than Ardent Health
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Ardent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardent Health and related companies with MarketBeat.com's FREE daily email newsletter.
